

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/563193
Applicant : Ludwig NEYSES
Filed : 03/15/2006
TC/A.U. : not known
Examiner : not known
Confirmation No. : not known

Docket No. : WO05002495US

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a copy of an Information Disclosure Statement by Applicant ("IDS") (Form PTO/SB/08A and 08B as required) together with copies of the cited documents. It is respectfully requested that the cited documents be considered by the Examiner and the IDS be initialed by the Examiner to indicate such consideration and that a copy of such be returned to Applicant(s).

Pursuant to 37 C.F.R. § 1.97, the submission of this IDS is not to be construed as a representation that a search has been made and is not to be construed as an admission that the information cited in this IDS is material to patentability. This IDS is being submitted under:

37 C.F.R. §1.97(b)

- (1) – i.e. within 3 mo of filing date of national ap (other than under 1.53(d))
- (2) – i.e. within 3 mo of date of entry in national stage (international ap 1.491)
- (3) – i.e. before mailing of first Office Action on the merits
- (4) – i.e. before mailing of first Office Action after filing RCE under 1.114

37 C.F.R. §1.97(c) – i.e. after time period of 1.97(b) and before an action closing prosecution (mailing date of final action 1.113, NOA 1.311, etc.) and is accompanied by:

- [] (1) – one of the statements of 1.97(e) below; OR
[] (2) – the fee set forth in 1.17(p) and enclosed.

37 C.F.R. §1.97(d) – i.e. after time period of 1.97(c) and IDS is filed on or before issue fee and is accompanied by:

- [] (1) – one of the statements of 1.97(e) below; AND (2) – the fee set forth in 1.17(p) and enclosed.

37 C.F.R. §1.97(e) statement:

- [] (1) That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
- [] (2) That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

Respectfully submitted,

Dated: 03/15/2006



Digitally signed by Alan
Heimlich
DN: CN = Alan Heimlich,
C = US, O = Heimlich Law

Alan Heimlich / Reg. No. 48808
Customer No. 40418
Tel: +1 408 253 3860

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/563193
		Filing Date	03/15/2006
		First Named Inventor	Ludwig NEYSES
		Art Unit	
		Examiner Name	
Sheet	1	of	2
		Attorney Docket Number	WO05002495US

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/563193
				Filing Date	03/15/2006
				First Named Inventor	Ludwig NEYSES
				Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	WO05002495US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		SCHUH KAI ET AL : "Plasma membrane Ca ²⁺ ATPase 4 is required for sperm motility and male fertility" JOURNAL OF BIOLOGICAL CHEMISTRY, vol . 279, no . 27, 2 July 2004 (2004-07-02), pages 28220-28226, XP008036550 ISSN : 0021-9258			
		KANWAR U ET AL : "GOSSYPOL INHIBITION OF CA++ UPTAKE AND CA++-ATPASE IN HUMAN EJACULATED SPERMATOZOAL PLASMA MEMBRANE VESICLES" CONTRACEPTION, GERON-X, INC ., LOS ALTOS, CA, US, vol . 39, no . 4, 1 April 1989 (1989-04-01), pages 431-445, XP000561575 ISSN : 0010-7824			
		BREITBART H ET AL : "THE ROLE OF CALCIUM AND CA ²⁺ -ATPASE IN MAINTAINING MOTILITY IN RAM SPERMATOZOA" JOURNAL OF BIOLOGICAL CHEMISTRY . (MICROFILMS), AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol . 260, no . 21, 25 September 1985 (1985-09-25), pages 11548-11553, XP001009929			
		PATNI ANIL K ET AL : "Role of intracellular calcium in the spermicidal action of 2',4'-dichlorobenzamil, a novel contact spermicide" JOURNAL OF PHARMACY AND PHARMACOLOGY, vol . 53, no . 10, October 2001 (2001-10), pages 1387-1392, XP008036557 ISSN : 0022-3573			
		SCHUH KAI ET AL : "The sarcolemmal calcium pump PMCA : An effector of platelet aggregation ." CIRCULATION, vol . 106, no . 19 Supplement, 5 November 2002 (2002-11-05), pages 11-79, XP008036566 & ABSTRACTS FROM SCIENTIFIC SESSIONS ; CHICAGO, IL, USA ; NOVEMBER 17-20, 2002 ISSN : 0009-7322			
		YANG Z ET AL : "Na ⁺ -Ca ²⁺ exchange activity is localized in the T-tubules of rat ventricular myocytes" CIRCULATION RESEARCH, vol . 91, no . 4, 23 August 2002 (2002-08-23), pages 315-322, XP008036552 ISSN : 0009-7330			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.